These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28144285)

  • 1. The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillance.
    Murray NP; Reyes E; Fuentealba C; Aedo S; Jacob O
    Ecancermedicalscience; 2017; 11():711. PubMed ID: 28144285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in Chile.
    Murray NP; Reyes E; Fuentealba C; Jacob O; Orellana N
    Asian Pac J Cancer Prev; 2014; 15(21):9335-9. PubMed ID: 25422221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer.
    Murray NP; Reyes E; Fuentealba C; Orellana N; Jacob O
    J Oncol; 2014; 2014():612674. PubMed ID: 25210517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Dueñas R
    Arch Esp Urol; 2014 Oct; 67(8):684-91. PubMed ID: 25306986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3375-3381. PubMed ID: 30583343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.].
    Murray NP; Fuentealba C; Reyes E; Jacob O
    Arch Esp Urol; 2017 Jun; 70(5):503-512. PubMed ID: 28613202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
    Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
    Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head to Head Comparison of the Chun Nomogram, Percentage Free PSA and Primary Circulating Prostate Cells to Predict the Presence of Prostate Cancer at Repeat Biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2016; 17(6):2941-6. PubMed ID: 27356715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1577-1583. PubMed ID: 29936782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How localized is pathologically localized prostate cancer? The use of secondary circulating prostate cells as a marker of minimal residual disease and their association with patient outcome.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
    Turk J Urol; 2017 Dec; 43(4):456-461. PubMed ID: 29201508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Ecancermedicalscience; 2019; 13():934. PubMed ID: 31281431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
    Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
    Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
    Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and characteristics of primary circulating prostate cells; association with micrometastasis and implications for surgical treatment of men with prostate cancer.
    Murray NP; Reyes E; Badínez L; Orellana N; Dueñas R; Fuentealba C
    Arch Esp Urol; 2010 Jun; 63(5):345-53. PubMed ID: 20587839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer.
    Murray NP; Reyes E; Fuentealba C; Orellana N; Morales F; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(13):5365-70. PubMed ID: 26225679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the Presence of Primary Circulating Prostate Cells Imply the Presence of Agressive Prostate Cancer with Early Biochemical Failure: a Comparison with the Walz Nomogram.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Orellana S; Jacob O
    Asian Pac J Cancer Prev; 2016; 17(7):3089-93. PubMed ID: 27509934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological upgrading and upstaging at radical prostatectomy in Jamaican men with low-risk prostate cancer.
    Morrison BF; Aiken WD; Reid G; Mayhew R; Hanchard B
    Ecancermedicalscience; 2019; 13():971. PubMed ID: 31921342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.